Cargando...
Targeting cancers through TCR-peptide/MHC interactions
Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies that target hematological cancers in 2018. A significant issue faced by CAR-T therapies is the lack of tumor-specific bio...
Gardado en:
| Publicado en: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6921533/ https://ncbi.nlm.nih.gov/pubmed/31852498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0812-8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|